GSK’s Blenrep Combo Scores Phase III Win in Multiple Myeloma

GSK on Monday posted findings from an interim analysis of the Phase III DREAMM-7 trial showing that its antibody-drug conjugate Blenrep (belantamab mafodotin), when used in a three-drug regimen, led to a significant improvement in progression-free survival in patients with relapsed or refractory multiple myeloma.